Symbiotec Pharmalab Limited
Promoters ANIL SATWANI · KASHISH SATWANI · SUSHIL SATWANI · SATWANI HOLDINGS LLP
Against an issue price of ₹988. Split- and bonus-adjusted official closes — a past move, never a forecast.
Symbiotec Pharmalab Limited raised ₹2,180 crore through a mainboard initial public offer.
The filing places it in Pharmaceuticals & Biotechnology and names four promoters: ANIL SATWANI, KASHISH SATWANI, SUSHIL SATWANI and SATWANI HOLDINGS LLP.
The book was open from 24 August 2026 to 27 August 2026.
The issue was priced at ₹988 a share, from a band of ₹938 to ₹988.
As of the exchange's 27-Aug-2026 19:00:00 update the book was subscribed 71.3 times the shares on offer, counting bids on NSE and BSE together.
Against their reserved portions: qualified institutional buyers 172.03 times, non-institutional investors 73.63 times, retail investors 12.96 times and employees 15.41 times. Those portions add up to the whole offer; the sub-categories below each one are already counted inside it.
7.27 crore shares were bid at cut-off — applications that accept whatever price the issue is finally set at rather than naming one.
The shares listed on 1 September 2026.
The last official close on file is ₹1,133 (11 September 2026), which is 14.7% above the issue price.
It now trades as SYMBIOTEC, and its filed financials are on its company page.
Shares sold in the issue at ₹988 last closed at ₹1,133.45.
See SYMBIOTEC’s filed financials and price history →Official exchange closes, restated for splits, bonuses and rights issues since listing. A record of past price movement, not a forecast.
- How it was priced
- Book-built — the price was discovered inside a band from the bids received
- Listing sought at
- BSE And NSE
- Registered office
- Northern India
- Company website
- www.symbiotec.com
- Registrar
- MUFG Intime India Private Limited
- Lead managers
- JM Financial Limited
- Avendus Capital Private Limited
- Motilal Oswal Investment Advisors Limited and Nomura Financial Advisory and Securities (India) Private Limited
- Bidding opens24 Aug 2026
- Bidding closes27 Aug 2026
- Basis of allotmentnot published
Not published in the exchange feeds we ingest — we do not estimate it.
- Listing1 Sept 2026
Investors have bid for 71.26 times the shares on offer. Each category below has its own reserved portion, and those portions add up to the whole offer.
Bids placed on NSE alone, excluding BSE. It is smaller than the 71.26x headline above and the two must never be compared or added together.
Every bid names a price, or accepts whatever the final price turns out to be. This shows how many shares have been bid for at each price or above it — so the bar at the top of the band counts only the bids willing to pay it.
The columns are near-identical because they are: demand falls only 0.03% between ₹938 and ₹988, so almost every bid was willing to pay the top of the band. The axis starts at zero — the flatness is the finding, not a missing scale.
These accept whatever price the issue is finally set at, so they have no place on the price axis and are not in the chart.
How much of the demand falls away between the bottom and the top of the band.
Cumulative shares bid at or above each price in the band, from the exchange's own demand schedule. Bids placed at cut-off carry no price and are counted separately.
We have not extracted an anchor allotment list for this issue.
- Anchor investors — first trancheSEBI ICDR 2018 Reg. 32(5)(b) — 50% of the anchor allocation, 30 days from allotment1 Oct 202650% of this tranche
- Anchor investors — second trancheSEBI ICDR 2018 Reg. 32(5)(a) — the remaining 50% of the anchor allocation, 90 days from allotment30 Nov 202650% of this tranche
- All other pre-issue capitalSEBI ICDR 2018 Reg. 17 — all other pre-issue capital, 6 months from allotment1 Mar 2027whole tranche releases on this date
- Promoters' minimum contributionSEBI ICDR 2018 Reg. 16(1)(a) — promoters' minimum contribution, 18 months from allotment1 Mar 2028whole tranche releases on this date
Computed from the SEBI ICDR 2018 lock-in rules, not disclosed by the issuer or the exchange. The regulation counts from the date of allotment, which no feed we ingest publishes, so these are counted from the listing date and fall at most two to three business days later than the true expiry.
The "Basis for Offer Price" chapter states the earnings the price was set against and the multiples it implies. We have not extracted it for this issue — several offer documents are served as .zip archives or as scanned pages with no text layer.
We have not extracted this section from the offer document for this issue yet. It is read from the abridged prospectus, and several offer documents are served as .zip archives or as scanned pages with no text layer.
What the company says it will do with the money it raises. Only the fresh-issue portion reaches the company; anything raised through an offer for sale goes to the shareholders selling.
- Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by our Company standalone basis) amounted to ₹3,497.81 million. We propose to utilize an estimated amount of up to ₹1,125.00 million from the Net Proceeds towards pre-payment and/or repayment of all, or a portion, of certain outstanding borrowings availed by us and the interest accrued thereon.1,125
- General corporate purposes We propose to utilize up to ₹[●] million of the balance Net Proceeds towards general corporate purposes and our business requirements as approved by the Board, from time to time, subject to such utilization for general corporate purposes not exceeding 25% of the Gross Proceeds, in compliance with the SEBI ICDR Regulations. The respective portion of the proceeds from the Offer for Sale shall be received by each of the Selling Shareholders, after deducting their respecti—
Figures as filed by the issuer in its offer document.
The offer document must name the listed companies the issuer considers comparable, and print their valuation figures beside its own. This is that list — the issuer’s choice of comparison, not ours.
| Company | P/E | P/B | RoNW | EPS | Income |
|---|---|---|---|---|---|
| Cohance Lifesciences Limited | 95.2 | — | 7.0% | 4.69 | ₹22,686 cr |
| Concord Biotech Limited | 62.5 | — | 14.0% | 24.78 | ₹10,549 cr |
| Divi's Laboratories Limited | 90.4 | — | 16.5% | 96.75 | ₹1,05,600 cr |
| Laurus Labs Limited | 113.5 | — | 16.8% | 16.47 | ₹68,129 cr |
The issuer's own figures as printed at the head of the same table — its claim about itself, on the same basis as its claims about the companies below.
Figures as PRINTED by the issuer in its own offer document. The comparison set is the issuer's choice, not ours.
| Firm | Issues | Typical listing move | Below issue @30d | @90d | @180d |
|---|---|---|---|---|---|
Avendus Capital Private Limited 2024 – 2026 | 7 2 measurable | +1.1% | — | — | 0 of 2 |
JM Financial Limited 2021 – 2026 | 67 14 measurable | +13.3% | 4 of 7 | 0 of 2 | 0 of 3 |
Motilal Oswal Investment Advisors Limited and Nomura Financial Advisory and Securities Private Limited 2026 – 2026 | 1 | +11.1% | — | — | — |
| Firm | Issues | Typical listing move | Below issue @30d | @90d | @180d |
|---|---|---|---|---|---|
Mufg Intime India Private Limited 2025 – 2026 | 76 11 measurable | +20.8% | 0 of 4 | 1 of 1 | 1 of 4 |
A count of what happened to the other issues each firm was named on, computed from exchange closes. Not a rating, not a ranking, and not a view on the firm.
- Prospectus· PDF · exchange archive31 Aug 2026
- Red herring prospectus (RHP)· ZIP · exchange archive18 Aug 2026
- Red herring prospectus (RHP)· ZIP · exchange archive
- Draft red herring prospectus (DRHP)· PDF · exchange archive19 Dec 2025
- Abridged prospectus· PDF · exchange archive19 Aug 2026
- Anchor investor allotment· ZIP · exchange archiveThis document is a scan with no text layer — readable by eye, not by machine.
- Financial ratios advertisement· ZIP · exchange archive
- In-principle approval (XBRL)· XML · exchange archive
Filed with SEBI and the exchanges by the issuer. These are the source for every figure on this page.
Compiled from NSE and SEBI offer documents and exchange feeds. A description of the issue and of the bids received — not investment advice, and not a view on whether to apply. No grey-market premium, no allotment lookup and no listing-gain estimate is published here.